This section is intended for UK healthcare professionals. If you are a member of the public click here. If you have been prescribed ADCETRIS click here.

Publications

The below clinical papers can be requested from Takeda Medical Information

Request clinical papers

R/R HL Pre-ASCT

Eyre et al. Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin (BV) in relapsed, refractory classical Hodgkin lymphoma (R/R HL) in the transplant naïve setting. British Journal of Haematology. 2017; doi:10.1111/bjh.14898

R/R HL Post-ASCT

Chen R, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016; 128 (12): 1562-6

Younes A, et al. Results of a Pivotal Phase II Study of brentuximab Vedotin for Patients with Relapsed or Refractory Hodgkin’s Lymphoma. J Clin Oncol. 2012; 30: 2183-9

R/R HL & R/R sALCL Reuse

Bartlett NL, et al. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Haem Onc. 2014; 7 (24): 1-8

R/R HL Consolidation

Moskowitz CH, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015; 385: 1853-62

R/R sALCL

Pro B, et al. Brentuximab vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study. J Clin Oncol. 2012; 30 (18). 2190-6

Pro B, et al. Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. Presented at ASH 2016. Abstract 4144

Request clinical papers

Meeting reports
Post-ICML

Takeda sponsored satellite session report with KOL video footage

An interactive report on ‘How best to integrate targeted treatment in relapsed/refractory (R/R) Hodgkin lymphoma’.

View

Patient support materials
patient guide

Patient Support Booklet

Takeda Oncology has developed this booklet providing information for patients who have been prescribed ADCETRIS for Hodgkin lymphoma or systemic Anaplastic Large Cell Lymphoma.

Currently not available

management tracker

Peripheral Neuropathy Diary

A diary for patients to help them track any symptoms and feelings of neuropathy.

Order free printed copy

Download

Adcetris Nurse PN A4 poster

Peripheral Neuropathy A4 Poster

A poster highlighting the symptoms that may indicate the presence of peripheral neuropathy.

Order free printed copy

Download

Adcetris Nurse PN A5

Peripheral Neuropathy A5 Leaflet

A leaflet highliting the symptoms that may indicate the presence of peripheral neuropathy.

Order free printed copy

Download

Adverse events should be reported. In the United Kingdom, reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.

Adverse events should also be reported to Takeda on 01628 537900 or e-mail DSO-UK@takeda.com.